CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Contineum Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.44+0.36 (+5.08%)
Close on Oct 19, 2026
- Market cap
- $278.76M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
81.2%
31M of 38M shares
Institutional holders
102
29 new, 15 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 31 sales
Net sold $1.86M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 2,448,979 | 7.90% | 13G (passive) | Dec 31, 2025 |
| Balyasny Asset Management L.P. | 2,417,723 | 7.40% | 13G (passive) | Mar 31, 2026 |
| Dmitry Balyasny | 2,335,550 | 7.14% | 13G (passive) amendment | Jun 30, 2026 |
| Balyasny Asset Management Holdings LP | 2,312,800 | 7.60% | 13G (passive) | Dec 31, 2025 |
| RA Capital Management, L.P. | 2,179,711 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 2,049,493 | 6.30% | 13G (passive) | Jun 30, 2026 |
| Johnson & Johnson | 1,979,173 | 10.70% | 13G (passive) | Apr 9, 2024 |
| Franklin Resources, Inc. | 1,879,367 | 6.20% | 13G (passive) amendment | Dec 31, 2025 |
| Suvretta Capital Management, LLC | 1,720,000 | 9.30% | 13G (passive) | Apr 5, 2024 |
| Millennium Group Management LLC | 1,658,349 | 5.10% | 13G (passive) | Apr 13, 2026 |
| Franklin Advisers, Inc. | 1,655,548 | 7.70% | 13G (passive) amendment | Sep 30, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. | 1,441,249 | 5.60% | 13G (passive) amendment | Dec 31, 2024 |
| Joseph Edelman | 1,441,249 | 7.50% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CTNM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2,841,334 | 7.55% | $46.57M | – | 0.85% |
| Jupiter Topco LLC | 2,734,836 | 7.27% | $44.77M | New | 0.02% |
| BlackRock, Inc. | 2,064,345 | 5.49% | $33.83M | +1,395,222 | 0.00% |
| Johnson & Johnson | 1,979,173 | 5.26% | $32.44M | – | 4.06% |
| Franklin Resources Inc | 1,839,227 | 4.89% | $30.14M | – | 0.01% |
| Balyasny Asset Management L.P. | 1,522,793 | 4.05% | $24.96M | −162,842 | 0.03% |
| Vanguard Capital Management LLC | 1,321,356 | 3.51% | $21.66M | +107,183 | 0.00% |
| Perceptive Advisors LLC | 1,255,592 | 3.34% | $20.58M | – | 0.31% |
| FMR LLC | 1,040,130 | 2.76% | $17.05M | +225,259 | 0.00% |
| Millennium Management LLC | 931,709 | 2.48% | $15.27M | −603,740 | 0.01% |
| Great Point Partners LLC | 921,481 | 2.45% | $15.10M | +121,283 | 2.85% |
| Longaeva Partners L.P. | 812,757 | 2.16% | $13.32M | +80,669 | 0.29% |
| Ikarian Capital, LLC | 807,874 | 2.15% | $13.24M | – | 1.43% |
| Sectoral Asset Management Inc | 727,587 | 1.93% | $11.93M | – | 8.32% |
| Geode Capital Management, LLC | 693,188 | 1.84% | $11.36M | +411,150 | 0.00% |
| Hhlr Advisors, Ltd. | 669,337 | 1.78% | $10.97M | – | 1.32% |
| Red Tree Management, LLC | 638,158 | 1.70% | $10.46M | – | 7.10% |
| Versant Venture Management, LLC | 542,628 | 1.44% | $8.89M | – | 5.47% |
| Goldman Sachs Group Inc | 497,255 | 1.32% | $8.15M | +190,147 | 0.00% |
| Boxer Capital Management, LLC | 494,000 | 1.31% | $8.10M | – | 0.61% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 31M | 81.2% | 29 / 32 | 19 / 15 | 8M | 5M |
| Q1 2026 | 90 | 31M | 81.2% | 22 / 29 | 22 / 11 | 6M | 4M |
| Q4 2025 | 80 | 30M | 78.7% | 31 / 29 | 7 / 11 | 13M | 1M |
| Q3 2025 | 62 | 18M | 46.5% | 14 / 18 | 18 / 22 | 5M | 2M |
| Q2 2025 | 70 | 14M | 36.9% | 27 / 12 | 22 / 20 | 1M | 3M |
| Q1 2025 | 63 | 15M | 40.6% | 7 / 19 | 18 / 5 | 0M | 1M |
| Q4 2024 | 62 | 16M | 42.0% | 13 / 28 | 10 / 3 | 3M | 1M |
| Q3 2024 | 52 | 14M | 36.5% | 9 / 15 | 16 / 5 | 2M | 1M |
| Q2 2024 | 49 | 13M | 34.6% | 49 / 0 | 0 / 0 | 13M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CTNM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 982,259 | 2.61% | $16.10M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 646,661 | 1.72% | $10.60M | 0.01% | Jun 30, 2026 |
| Select Health Care Portfolio | 450,000 | 1.20% | $6.07M | 0.10% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 330,090 | 0.88% | $5.11M | 0.44% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 308,749 | 0.82% | $5.06M | 0.01% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 295,058 | 0.78% | $4.57M | 0.40% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 294,824 | 0.78% | $4.57M | 0.01% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 280,000 | 0.74% | $4.34M | 0.14% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 244,589 | 0.65% | $4.01M | 0.03% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 224,900 | 0.60% | $3.48M | 0.16% | Jul 31, 2026 |
| iShares Biotechnology ETF | 205,163 | 0.55% | $3.36M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Stock Fund | 176,600 | 0.47% | $2.74M | 0.20% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 126,427 | 0.34% | $1.71M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 115,502 | 0.31% | $1.56M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 90,316 | 0.24% | $1.48M | 0.10% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carmine N. Stengone | CEO and President, Director | 19,717 | 0.05% | Sep 8, 2026 |
| Daniel S. Lorrain | Chief Scientific Officer | 145,337 | 0.39% | Jul 10, 2026 |
| Tim Watkins | CMO & Head of Development | 8,961 | 0.02% | Jul 1, 2026 |
| John Stephen Healy | General Counsel and Corp Sec | – | – | Jan 30, 2026 |
| Peter T. Slover | Chief Financial Officer | – | – | Jan 30, 2026 |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 12,800 | 0.03% | Jan 31, 2025 |
| Troy A. Ignelzi | Director | – | – | Jun 26, 2026 |
| Evert B. Schimmelpennink | Director | – | – | Jun 26, 2026 |
| Gines Diego Miralles | Director | – | – | Jun 26, 2026 |
| Todd R. Brady | Director | – | – | Jun 26, 2026 |
| Sarah Boyce | Director | – | – | Jun 26, 2026 |
| Olivia C. Ware | Director | – | – | Jun 26, 2026 |
| Lori Lyons-Williams | Director | – | – | Jun 26, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Carmine N. Stengone CEO and President, Director | Sep 8, 2026 | Option exercise | +2,500 | $1.01 | $2.53K | 19,717 |
| Carmine N. Stengone CEO and President, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,500 | $16.46 | $41.15K | 17,217 |
| Carmine N. Stengone CEO and President, Director | Aug 3, 2026 | Option exercise | +2,500 | $1.01 | $2.53K | 19,717 |
| Carmine N. Stengone CEO and President, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −2,500 | $16.01 | $40.03K | 17,217 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 9, 2026 | Option exercise | +25 | $1.01 | $25 | 135,227 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 9, 2026 | Sale(10b5-1 plan) | −25 | $16.00 | $400 | 135,202 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 8, 2026 | Sale(10b5-1 plan) | −1,015 | $16.00 | $16.24K | 135,202 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 8, 2026 | Option exercise | +1,015 | $1.01 | $1.03K | 136,217 |
| Carmine N. Stengone CEO and President, Director | Jul 8, 2026 | Option exercise | +2,500 | $1.01 | $2.53K | 19,717 |
| Carmine N. Stengone CEO and President, Director | Jul 8, 2026 | Sale(10b5-1 plan) | −2,500 | $16.00 | $40.00K | 17,217 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 1, 2026 | Option exercise | +4,183 | $1.01 | $4.22K | 143,555 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −5,852 | $15.67 | $91.70K | 137,703 |
| Daniel S. Lorrain Chief Scientific Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −2,501 | $16.24 | $40.62K | 135,202 |
| Daniel S. Lorrain Chief Scientific Officer | Jun 30, 2026 | Option exercise | +28,826 | $1.01 | $29.11K | 168,198 |
| Daniel S. Lorrain Chief Scientific Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −28,826 | $16.04 | $462.37K | 139,372 |
| Carmine N. Stengone CEO and President, Director | Jun 30, 2026 | Option exercise | +2,500 | $1.26 | $3.15K | 27,217 |
| Carmine N. Stengone CEO and President, Director | Jun 30, 2026 | Option exercise | +7,500 | $1.01 | $7.58K | 24,717 |
| Carmine N. Stengone CEO and President, Director | Jun 30, 2026 | Sale(10b5-1 plan) | −10,000 | $16.01 | $160.10K | 17,217 |
| Tim Watkins CMO & Head of Development | Jun 30, 2026 | Sale(10b5-1 plan) | −10,833 | $16.02 | $173.54K | 8,961 |
| Tim Watkins CMO & Head of Development | Jun 30, 2026 | Option exercise | +10,833 | $4.50 | $48.75K | 19,794 |
| Daniel S. Lorrain Chief Scientific Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −4,170 | $13.16 | $54.88K | 139,372 |
| Daniel S. Lorrain Chief Scientific Officer | May 1, 2026 | Sale(10b5-1 plan) | −3,870 | $13.06 | $50.54K | 143,842 |
| Daniel S. Lorrain Chief Scientific Officer | May 1, 2026 | Sale(10b5-1 plan) | −300 | $13.84 | $4.15K | 143,542 |
| Daniel S. Lorrain Chief Scientific Officer | Apr 6, 2026 | Sale(10b5-1 plan) | −4,170 | $13.43 | $56.00K | 147,712 |
| Daniel S. Lorrain Chief Scientific Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −4,170 | $15.01 | $62.59K | 151,882 |
| Tim Watkins CMO & Head of Development | Mar 2, 2026 | Sale(10b5-1 plan) | −3,611 | $15.02 | $54.24K | 0 |
| Tim Watkins CMO & Head of Development | Mar 2, 2026 | Option exercise | +3,611 | $4.50 | $16.25K | 3,611 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 25, 2026 | Option exercise | +3,824 | $1.01 | $3.86K | 159,876 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −3,824 | $16.01 | $61.22K | 156,052 |
| Carmine N. Stengone CEO and President, Director | Feb 25, 2026 | Sale(10b5-1 plan) | −2,700 | $16.02 | $43.25K | 14,954 |
| Carmine N. Stengone CEO and President, Director | Feb 25, 2026 | Option exercise | +2,700 | $1.26 | $3.40K | 17,654 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −4,300 | $16.03 | $68.93K | 156,052 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 24, 2026 | Option exercise | +4,300 | $1.01 | $4.34K | 160,352 |
| Carmine N. Stengone CEO and President, Director | Feb 24, 2026 | Sale(10b5-1 plan) | −4,400 | $16.02 | $70.49K | 14,954 |
| Carmine N. Stengone CEO and President, Director | Feb 24, 2026 | Option exercise | +4,400 | $1.26 | $5.54K | 19,354 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 19, 2026 | Option exercise | +100 | $1.01 | $101 | 156,152 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 19, 2026 | Sale(10b5-1 plan) | −100 | $16.00 | $1.60K | 156,052 |
| Carmine N. Stengone CEO and President, Director | Feb 11, 2026 | Sale(10b5-1 plan) | −400 | $16.00 | $6.40K | 14,954 |
| Carmine N. Stengone CEO and President, Director | Feb 11, 2026 | Option exercise | +400 | $1.26 | $504 | 15,354 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 11, 2026 | Sale(10b5-1 plan) | −400 | $16.00 | $6.40K | 156,052 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 11, 2026 | Option exercise | +400 | $1.01 | $404 | 156,452 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 3, 2026 | Sale(10b5-1 plan) | −1,170 | $15.25 | $17.84K | 156,052 |
| Daniel S. Lorrain Chief Scientific Officer | Feb 3, 2026 | Sale(10b5-1 plan) | −3,000 | $14.82 | $44.46K | 157,222 |
| Tim Watkins CMO & Head of Development | Jan 28, 2026 | Sale(10b5-1 plan) | −811 | $14.48 | $11.74K | 0 |
| Tim Watkins CMO & Head of Development | Jan 28, 2026 | Option exercise | +3,611 | $4.50 | $16.25K | 3,611 |
| Tim Watkins CMO & Head of Development | Jan 28, 2026 | Sale(10b5-1 plan) | −2,800 | $14.09 | $39.45K | 811 |
| Daniel S. Lorrain Chief Scientific Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −500 | $11.13 | $5.57K | 160,222 |
| Daniel S. Lorrain Chief Scientific Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −3,670 | $10.35 | $37.98K | 160,722 |
| Tim Watkins CMO & Head of Development | Dec 29, 2025 | Option exercise | +3,611 | $4.50 | $16.25K | 3,611 |
| Tim Watkins CMO & Head of Development | Dec 29, 2025 | Sale(10b5-1 plan) | −3,611 | $12.06 | $43.55K | 0 |
| Daniel S. Lorrain Chief Scientific Officer | Dec 23, 2025 | Sale(10b5-1 plan) | −4,170 | $12.23 | $51.00K | 164,392 |
| Daniel S. Lorrain Chief Scientific Officer | Nov 25, 2024 | Sale(10b5-1 plan) | −1,010 | $16.02 | $16.18K | 168,562 |
| Daniel S. Lorrain Chief Scientific Officer | Nov 18, 2024 | Sale(10b5-1 plan) | −99 | $17.05 | $1.69K | 169,572 |
| Daniel S. Lorrain Chief Scientific Officer | Nov 18, 2024 | Sale(10b5-1 plan) | −6,091 | $16.37 | $99.71K | 169,671 |
| Stephen L. Huhn CMO & Sr VP, Clinical Dev. | Aug 13, 2024 | Option exercise | +12,800 | $1.01 | $12.93K | 12,800 |
| Versant Vantage I, L.P. 10% owner | Apr 9, 2024 | Conversion | +2,531 | – | – | 2,531 |
| Versant Vantage I, L.P. 10% owner | Apr 9, 2024 | Conversion | +148,312 | – | – | 148,312 |
| Versant Vantage I, L.P. 10% owner | Apr 9, 2024 | Conversion | +391,785 | – | – | 391,785 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lorrain Daniel Officer | Oct 1, 2026 | 4,170 | $55.96K | Oct 1, 2026 | Restricted Stock Units |
| Stengone Carmine Director, Officer | Sep 8, 2026 | 2,500 | $41.75K | Sep 8, 2026 | Exercise of Stock Options |
| Lorrain Daniel Officer | Sep 1, 2026 | 9,520 | $154.60K | Sep 1, 2026 | Exercise of Stock Options |
| Stengone Carmine Director, Officer | Aug 3, 2026 | 2,500 | $38.73K | Aug 3, 2026 | Exercise of Stock Options |
| Lorrain Daniel Officer | Aug 3, 2026 | 9,520 | $147.46K | Aug 3, 2026 | Restricted Stock Units |
| Stengone Carmine Director, Officer | Jul 8, 2026 | 2,500 | $36.40K | Jul 8, 2026 | Exercise of Stock Options |
| Lorrain Daniel Officer | Jul 1, 2026 | 9,520 | $156.03K | Jul 1, 2026 | Exercise of Stock Options |
| Lorrain Daniel Officer | Jun 30, 2026 | 28,826 | $432.39K | Jun 30, 2026 | Exercise of Stock Options |
| Stengone Carmine Director, Officer | Jun 30, 2026 | 10,000 | $150.00K | Jun 30, 2026 | Exercise of Stock Options |
| Watkins Timothy Officer | Jun 30, 2026 | 10,833 | $162.50K | Jun 30, 2026 | Exercise of Stock Options |
| Lorrain Daniel Officer | Jun 1, 2026 | 4,170 | $56.25K | Jun 1, 2026 | Restricted Stock Units |
| Lorrain Daniel Officer | May 1, 2026 | 4,170 | $53.46K | May 1, 2026 | Restricted Stock Units |
| Lorrain Daniel Officer | Apr 6, 2026 | 914 | $12.28K | Apr 6, 2026 | Restricted Stock Units |
| Lorrain Daniel Officer | Feb 11, 2026 | 16,050 | $252.79K | Feb 11, 2026 | Exercise of Stock Options |
| Stengone Carmine Director, Officer | Feb 11, 2026 | 7,500 | $118.13K | Feb 11, 2026 | Exercise of Stock Options |